Andrew Waugh KC

Andrew Waugh KC has a general intellectual property practice with a particular emphasis on the patents and supplementary protection certificates. His background has led to a particular emphasis on chemical, pharmaceutical and bio-technical/genetic engineering matters as well as a broader commercial practice, including arbitrations involving a significant scientific/technical content.

Tribunals in front of which Andrew most frequently appears include not only the Courts of England and Wales, at first instance, Court of Appeal and Supreme Court level, but also before the Patent Office and the European Patent Office in Munich and the Hague.

• Graduated in 1980 from City University, London with a 1st class honours degree in Chemical and Administrative Studies which

included subjects on vitamin chemistry, structure and reactivity correlations and materials science and a thesis on pharmaceutical

Research and Development.

• Undertook the postgraduate Diploma in law in 1981.

• Called to the Bar 1982.

• Pupillage with Martin Moore-Bick 1982, 3 Essex Court (The Chambers of Kenneth Rokison KC).

• Pupillage with Simon Thorley 1983, 6 Pump Court (The Chambers of William Aldous KC).

• Queen's Counsel 1998.

• Head of Chambers at Three New Square IP from April 2018.

• Band 1 rated in Chambers and Partners and the Legal 500 for over 20 years

Vice Chair of the Intellectual Property Bar Association, Chancery Bar Association, AIPPLA, EPLAW

Co-Editor of Terrell on the law of Patents, 18th, 19th and 20th Editions.

Andrew has acted for many major international companies, including: Boston Scientific, Merck, GSK, Moderna, Eli Lilly, Bayer, Grunenthal, Takeda, Hoechst, Kirin-Amgen, Biogen, Angiotech, Lundbeck, New York University, Genentech, Doewe Egberts, Medtronic and Monsanto,

Andrew cycles daily and has a keen interest in all sports, especially cycling, football and rugby and is a past-Judicial Officer of the RFU Disciplinary Panel.

Supreme Court Cases include:

• Biogen v Medeva (Recombinant HCV, acting for Biogen)

• Conor v Angiotech (Taxol Eluting Stents, Acting for Angiotech)

• Synthon v GSK (Paroxetine, acting for GSK)

• Lundbeck v Mylan (Escitalopram, acting for Lundbeck)

• ICOS v Actavis (Tadalafil 5mg, Acting for ICOS)

• Actavis v Lilly (Pemetrexed, Acting for Lilly)

Other notable UK cases include:

• Semi-conductor devices (General Instrument v. Intel);

• Coding for compact discs (Optical Recording Corp. v. Hayden Labs);

• Flight simulators (Rediffusion Simulation v. Singer Link Miles);

• Contact lenses (Cibavision v Johnson & Johnson, Dublin);

• Copaxone (Generics/Mylan v Yeda Research and Development Co Ltd);

• Escitalopram (No.2) (Resolution Chemicals v H.Lundbeck);

• Antibodies to Amyloid-beta, for the treatment of Altzheimer’s Disease (Eli Lilly & Company v Janssen Alzheimer Immunotherapy);

• Cinacalcet for the treatment of bone disorders (Amgen v Accord);

• Anti-PD1 antibodies for the treatment of cancer (Merck Sharp & Dohme v Ono);

• Copaxone (discolouration) (Synthon v Teva);

• Sofosbuvir for the treatment of HCV (Idenix v Gilead);

• Vedolzumab (Entyvio) antibodies for the treatment of Ulcerative Colitis (Takeda v Roche);

• Adalimumab (Humira) for the treatment of RA inter alia (Samsung and Biiogen v AbbVie);

• Anti-IL23 antibodies for the treatment of psoriasis (Eli Lilly v Merck);

• Anti-IL17 antibodies for the treatment of psoriasis (Eli Lilly v Genentech);

• Anti-CGRP antibodies for the treatment of migraine (Eli Lilly v Teva);

• Slow release melatonin for insomnia (Neurim v Generics); Patch-worn

• Insulin pumps (Insulet v Roche);

• Arbitration (refaxamin - amorphous rifaximin) – Cipla v Salix;

• Factor IX inhibitor (Xaralto) (Teva and ors v Pfizer);

• Covid-19 mRNA vaccines (Moderna v Pfizer);

• Gene Therapy for type B haemophilia (Pfizer v UniQure);

• Eculizumab – complement inhibiting antibody (Alexion v Amgen).

A small selection of notable EPO cases includes:

• EP 2,996,521 – Acted for Doewe Egberts (Patentees) in resisting oppositions by Nestec, Belmoca, Caffitaly and ors before the OD

and the TBA.

• EP 1,623,350 - Acted for Genentech Inc (Proprietor) in T734/12 in respect of oppositions to EP in respect of “Therapy of

automimmune disease in a patient with an inadequate response of a TNF-alpha inhibitor” (novelty of distinct patient population);

• EP1,213,919 - Acted for ROVI/United Video Properties (Proprietor) ‘’Interactive Television Guide System”;

• EP 748,213 - Nektar Inc - Opposition by Lillly - Subject matter: Inhalable insulin - acted for Patentee before Opposition Division.

• EPA 96915698.3 - Genentech Inc. - subject matter: use of IGF-1 to sustain biological response .

• EP 237,545 - Kirin-Amgen (Opponents: ICI, Kyowa Hakko, Boehringer Mannheim). Subject matter: recombinant granulocyte colony

stimulating factor (G-CSF).

• EP 702,555 - Pfizer Ltd. - (Opponents Lilly Corp, ICOS Corp and ors) - Subject matter: PDEV inhibitors for the treatment of impotence.

• EP 37,255 - Eli Lilly (Opponent - Hoechst) Subject matter: Process for the recombination of the A & B chains of insulin.

• EP 203,945 - Bonzel (Opponent: Advanced Cardiovascular Systems) Subject matter: Catheters for Percutaneous Transluminal

Coronary Angioplasty.

• EP 235,691 - Hoechst (Opponent - Eli Lilly) Mixing ball for insulin suspensions.

• EP 237,545 - Kirin-Amgen (Opponents: ICI, Kyowa Hakko, Boehringer Mannheim). Subject matter: recombinant granulocyte colony

stimulating factor (G-CSF).; EP 182,442 - Biogen, Inc. (Opponents: Murex, Institut Pasteur, Immuno, Hexal-Biotech). Subject matter:

recombinant hepatitis B viral antigens.

• EP 148,605 - Amgen, Inc. (Opponents: Elanex, Behringwerke, Boerhringer-Mannheim Immuno) Subject matter: recombinant

erythropoietin.

• EP 209,539 - Genetics Institute, Inc (Opponents: Cilag GmbH, Kirin-Amgen, Inc) subject matter: “Homogeneous Erythropoietin”.

• EP 375,724 – New York University (Opposition by Incyte Corp). Subject matter: Bacteriocidal Permeability Increasing proteins (BPI).

Intellectual Property Silk of the Year

AI Awards

2013

IP/IT Silk of the Year, Chambers & Partners

Chambers & Partners

2010

IP/IT Silk of the Year, Chambers & Partners

Chambers & Partners

2009